featured
Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients With HR+/HER2− Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer
Oncologist 2020 Jul 03;[EPub Ahead of Print], F Miglietta, MV Dieci, V Tsvetkova, G Griguolo, G Vernaci, A Menichetti, G Faggioni, T Giarratano, E Mioranza, E Genovesi, E Cumerlato, M Bottosso, T Saibene, S Michieletto, M Lo Mele, P Conte, V GuarneriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.